Sell 3/25/2024Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D- from E+ on 3/25/2024 due to an increase in the volatility index and total return index.

Sell 3/6/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to E+ from D- on 3/6/2024 due to a decline in the volatility index.

Sell 3/1/2024Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 3/1/2024 due to a major decline in the efficiency index, growth index and solvency index. The quick ratio declined from 31.7 to 18.04, operating cash flow declined 24.12% from -$17.59M to -$21.83M, and net income declined 18.17% from -$33.14M to -$39.16M.

Sell 7/27/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 7/27/2023 due to an increase in the volatility index and total return index.

Sell 7/12/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 7/12/2023 due to a decline in the volatility index.

Sell 5/15/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 5/15/2023 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 35 to 50.2.

Sell 5/3/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 5/3/2023 due to a decline in the volatility index and total return index.

Sell 4/18/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 4/18/2023 due to an increase in the volatility index.

Sell 4/3/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 4/3/2023 due to a decline in the volatility index.

Sell 3/17/2023Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 3/17/2023 due to an increase in the volatility index and total return index.

Sell 3/1/2023Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 3/1/2023 due to a significant decline in the growth index, solvency index and efficiency index. Net income declined 326.87% from -$8.07M to -$34.43M, earnings per share declined from -$0.1 to -$0.4134, and EBIT declined 145.06% from -$16.28M to -$39.9M.

Sell 8/13/2021Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D from D- on 8/13/2021 due to a large increase in the growth index, efficiency index and total return index. Total capital increased 1.91% from $586.69M to $597.89M.

Sell 8/12/2021Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D- from D on 8/12/2021 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 105.29% from $318.52M to -$16.84M, and earnings per share declined from $0.3684 to $0.34.

Sell 4/20/2021Downgrade
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D from D+ on 4/20/2021 due to a decline in the volatility index and total return index.

Sell 4/5/2021Upgraded
Atea Pharmaceuticals, Inc. (AVIR) was upgraded to D+ from D on 4/5/2021 due to a significant increase in the solvency index, total return index and growth index. Operating cash flow increased 3,459.57% from -$9.48M to $318.52M, EBIT increased 418.01% from -$9.44M to $30.01M, and earnings per share increased from -$1.7431 to $0.3684.

Sell 1/27/2021None
Atea Pharmaceuticals, Inc. (AVIR) was downgraded to D from U on 01/27/2021.